Dyslipidemia and cardiovascular disease risk factor management in HIV-1-infected subjects treated with HAART in the Spanish VACH cohort.
HIV-1 infection; HIV-1 protease inhibitors; VACH; antiretroviral therapy; cardiovascular risk; coronary heart disease; dyslipidemia; non nucleoside reverse transcriptase inhibitors